176 related articles for article (PubMed ID: 1702566)
41. A comparison of Zoladex and DES in the treatment of advanced prostate cancer: results of a randomized, multicenter trial.
Citrin DL; Resnick MI; Guinan P; al-Bussam N; Scott M; Gau TC; Kennealey GT
Prostate; 1991; 18(2):139-46. PubMed ID: 1826048
[TBL] [Abstract][Full Text] [Related]
42. Correlation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated With Diverse Chemical Castrations.
Reis LO; Denardi F; Faria EF; Silva ED
Am J Mens Health; 2015 Sep; 9(5):430-4. PubMed ID: 25294865
[TBL] [Abstract][Full Text] [Related]
43. Zoladex treatment of symptomatic prostatic carcinoma.
Holdaway IM; Ibbertson HK; Croxson MS; Harvey V; Boulton J; Knox BS
Am J Clin Oncol; 1988; 11 Suppl 2():S123-6. PubMed ID: 2977267
[TBL] [Abstract][Full Text] [Related]
44. Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA).
Iversen P
Eur Urol; 1990; 18 Suppl 3():41-4. PubMed ID: 2151275
[TBL] [Abstract][Full Text] [Related]
45. Results obtained in the treatment of prostate cancer patients with Zoladex.
Williams G; Kerle DJ; Roe SM; Yeo T; Bloom SR
Prog Clin Biol Res; 1985; 185A():287-95. PubMed ID: 3162175
[No Abstract] [Full Text] [Related]
46. [A comparative study of the effect of Zoladex treatment versus orchiectomy in patients with advanced prostatic cancer].
Tsvetkov M; Kumanov Kh; Milkov V; Mladenov D; Neĭkov K
Khirurgiia (Sofiia); 1996; 49(1):5-8. PubMed ID: 8975090
[TBL] [Abstract][Full Text] [Related]
47. Recent developments in endocrine treatment of prostate cancer.
Vogelzang NJ; Kennealey GT
Cancer; 1992 Aug; 70(4 Suppl):966-76. PubMed ID: 1386283
[TBL] [Abstract][Full Text] [Related]
48. Patients' choice of treatment in stage D prostate cancer.
Cassileth BR; Soloway MS; Vogelzang NJ; Schellhammer PS; Seidmon EJ; Hait HI; Kennealey GT
Urology; 1989 May; 33(5 Suppl):57-62. PubMed ID: 2523612
[TBL] [Abstract][Full Text] [Related]
49. EORTC protocol 30853: orchidectomy versus zoladex plus flutamide in the management of metastatic carcinoma of the prostate. Interim statistical analysis of the side effects of treatment.
Robinson MR; Denis L; Newling DW; Sylvester R; De Pauw M
Cancer; 1990 Sep; 66(5 Suppl):1022-4. PubMed ID: 2144204
[TBL] [Abstract][Full Text] [Related]
50. Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue.
Ayub M; Levell MJ
Clin Endocrinol (Oxf); 1990 Mar; 32(3):329-39. PubMed ID: 2140542
[TBL] [Abstract][Full Text] [Related]
51. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen.
Akakura K; Bruchovsky N; Goldenberg SL; Rennie PS; Buckley AR; Sullivan LD
Cancer; 1993 May; 71(9):2782-90. PubMed ID: 7682149
[TBL] [Abstract][Full Text] [Related]
52. A new hormonal therapy for prostatic cancer: long-term clinical and hormonal response.
Ahmed SR; Grant JB; Shalet SM; Howell A; Costello CB; Weatherson T; Blacklock NJ
Br J Urol; 1986 Oct; 58(5):534-8. PubMed ID: 2946355
[TBL] [Abstract][Full Text] [Related]
53. Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer.
Goldspiel BR; Kohler DR
DICP; 1991; 25(7-8):796-804. PubMed ID: 1835221
[TBL] [Abstract][Full Text] [Related]
54. Bilateral orchidectomy in three metastatic prostate cancer patients with failed LHRH-agonist therapy.
Olapade-Olaopa EO; Oluwasola AO; Shonibare A; Falebita OA; Akang EE; Shokunbi MT
S Afr Med J; 2006 Sep; 96(9):810-1. PubMed ID: 17068650
[No Abstract] [Full Text] [Related]
55. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate.
Iversen P; Christensen MG; Friis E; Hornbøl P; Hvidt V; Iversen HG; Klarskov P; Krarup T; Lund F; Mogensen P
Cancer; 1990 Sep; 66(5 Suppl):1058-66. PubMed ID: 2144207
[TBL] [Abstract][Full Text] [Related]
56. Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group.
Denis L; Smith PH; De Moura JL; Newling DW; Bono A; Keuppens F; Robinson M; Mahler C; Sylvester R; De Pauw M
Eur Urol; 1990; 18 Suppl 3():34-40. PubMed ID: 2151274
[TBL] [Abstract][Full Text] [Related]
57. Effective long-term suppression of pituitary-gonadal axis in prostatic cancer by Zoladex (ICI 118,630).
Murphy GP; Greco J; Huben R
Urology; 1987 Nov; 30(5):482-3. PubMed ID: 2960064
[TBL] [Abstract][Full Text] [Related]
58. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.
Miller JI; Ahmann FR; Drach GW; Emerson SS; Bottaccini MR
J Urol; 1992 Mar; 147(3 Pt 2):956-61. PubMed ID: 1371568
[TBL] [Abstract][Full Text] [Related]
59. Prostate-specific antigen dynamics predict risk of progression in advanced prostate cancer treated with bicalutamide plus castration.
Altwein JE; Schmidt A
Urol Int; 2002; 68(4):220-5. PubMed ID: 12053021
[TBL] [Abstract][Full Text] [Related]
60. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
Lukkarinen O; Kontturi M
Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
